Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE  

作　　者：Haotian Zhou Xiaozhen Zhao Ruijun Zhang Miao Miao Wenwen Pei Zijun Li Yimin Li Jing He Zhanguo Li Xiaolin Sun 

机构地区：[1]Department of Rheumatology and Immunology,Clinical Immunology Center,Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis(BZ0135),Peking University People’s Hospital,No.11 Xizhimen South Street,100044,Beijing,China [2]Department of Rheumatology,Beijing Children’s Hospital,Capital Medical University,National Centre for Children’s Health,100045,Beijing,China [3]Peking-Tsinghua Center for Life Science,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第5期2041-2043,共3页信号转导与靶向治疗（英文）

基　　金：supported by the Natural Science Foundation of China (81971520,32141004,82171775);Project (RDGS2022-05) supported by Peking University People's Hospital Scientific Research Development Funds;Beijing Children's Hospital Young Investigator Program.

摘　　要：Dear Editor,Previous studies have proved that regulatory T cell(Treg)insufficiency contributed to the development of autoimmune conditions including systemic lupus erythematosus(SLE).Conventional immunosuppressive treatment was reported to downregulate beneficial Tregs together with pathogenic effector immune cells,which may impede a rapid achievement of optimal therapeutic effects.

关 键 词：GLUCOCORTICOID LUPUS ERYTHEMATOSUS SLE 

分 类 号：R593.24[医药卫生—内科学]